Back to Search
Start Over
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
- Source :
- PR Newswire. October 3, 2021
- Publication Year :
- 2021
-
Abstract
- Data demonstrated a 78% reduction in the risk of hospitalization or death in patients receiving single dose treatment of BRII-196/BRII-198 with zero deaths, versus eight compared to placebo, through the [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.677790411